Table 1.
Clinical parameters before and after injection of bevacizumab (avastin)
| Patient No. | Angiographic grading of iris new vessels | PAS | IOP in mmHg* | Best corrected visual acuity | Associated ocular conditions at inclusion | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before injection | 1 week | 2 months | Before | After | Before injection | 1 week | 2 months | Other procedures | Before injection | At the end of follow up | ||
| 1 | 4 | 3 | 4 | Stable | 48 | 50 | 20(T) | Cyclocryo | LP | No LP | Significant** cataract | |
| 2 | 4 | 2 | 1 | Stable | 19 | 15(T) | 15(T) | HM | HM | Significant**vit. hge. | ||
| 3 | 4 | 1 | 0 | No | No | 28 | 18(N) | 18(N) | 1/60 | 1/60 | ||
| 4 | 4 | 1 | 1 | 2/4 | Stable | 31 | 25 | 12(N) | A-G valve | C.F | 2/60 | |
| 5 | 4 | 2 | 2 | 2/4 | Stable | 29 | 17 | 16 | HM | CF | Significant**vit. hge. | |
| 6 | 4 | 0 | 0 | Stable | 21 | 18(T) | 17(T) | C.F | 1/60 | |||
| 7 | 3 | 1 | 1 | No | No | 27 | 14(N) | 15(N) | HM | 2/60 | Hyphaema | |
| 8 | 3 | 0 | 0 | No | No | 31 | 16(N) | 14(N) | 6/60 | 6/60 | ||
| 9 | 3 | 1 | 1 | 4/4 | Stable | 45 | 45 | 12 | Cyclocryo | LP | LP | |
| 10 | 3 | 2 | 3 | 2/4 | 20 | 17(T) | 22 | CF | CF | |||
| 11 | 3 | 1 | 0 | No | No | 19 | 14(N) | 15(N) | 1/60 | 2/60 | Mild vit. hge. | |
| 12 | 3 | 1 | 0 | 2/4 | Stable | 23 | 16(T) | 18(T) | 2/60 | 3/60 | ||
| 13 | 3 | 1 | 1 | No | No | 17 | 15(T) | 14(T) | 1/60 | 1/60 | ||
| 14 | 3 | 0 | 1 | Stable | 39 | 30 | 15(N) | A-G valve | CF | 4/60 | Mild vit. hge. | |
| 15 | 3 | 1 | 3 | Stable | 30 | 19(T) | 28 | CF | 2/60 | Mild vit. hge. | ||
| 16 | 2 | 0 | 0 | 21 | 15(N) | 16(N) | 3/60 | 4/60 | ||||
PAS = peripheral anterior synechiae, IOP = intraocular pressure, A-G valve = Ahmed glaucoma valve, vit. hge. = vitreous hemorrhage, LP = light perception, HM = hand motion, CF = counting fingers,
*
IOP is described in this table under systemic acetazolamide (750 mg/day Cyclocryo: Cyclocryotherapy) and topical β-blocker but when the letter (T) is added, only topical, β-blocker is used and if the letter (N) is added, no antiglaucoma drugs are used.
**
Significant cataract or vitreous hemorrhage is considered if the retina can't be visualized with indirect ophthalmoscopy through it.